Exelixis Executives Pump Up Shares Amid Strong Quarter, Hinting at Big Future Gains
Insider buying of 8,367 Exelixis shares signals confidence in upcoming oncology drug approvals, hinting at potential upside for shareholders.
3 minutes to read
Exelixis Inc
Exelixis Director David Johnson Buys 19,133 Options—Insider Bet on Future Growth Amid Executive Sell‑Offs
Exelixis insider activity: David Johnson’s new 19,133‑option grant shows bullish confidence amid market caution—what it means for investors and the company’s future.
3 minutes to read
Exelixis EVP sells 32,000 shares in routine RSU liquidation – market remains bullish and fundamentals steady.
Exelixis insider sale: 32,110 shares by EVP Haley Patrick J. shows routine RSU liquidity, not a warning—company remains solidly bullish with steady growth.
3 minutes to read
Exelixis CEO Donates 109,676 Shares to Charity, Signals Unprecedented Executive Philanthropy Flash!
Michael Morrissey’s rare charitable sale of 109,676 Exelixis shares—while keeping a 1.7% stake—signals strong executive confidence, boosts investor sentiment, and highlights leadership’s philanthropy amid a positive analyst upgrade and a robust biot…
3 minutes to read
Exelixis Insider Alert: Julie Smith Buys 86,500 Shares at a 40% Discount Amid Executive Sell‑Offs—A Possible Confidence Signal?
Julie Smith’s bulk buys at Exelixis reveal insider confidence – buy‑back at $18‑$19, well below market, signaling potential upside amid exec sales and a biotech pipeline poised for milestones.
3 minutes to read